arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

PROKIDNEY CORP.

PROK
$1.06 ▼ -0.06 (-5.33%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
24 Visible periods
15 Metrics
Peer-ranked Benchmarks
Price Chart
42
Health
Weak
Neutral
auto_awesome

Analytical Summary

PROKIDNEY CORP. shows mixed fundamentals. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap —
Dividend Yield —
Revenue Growth -32.1% ↘
Op. Margin —
ROIC 5.5% ↗
FCF / Share —
Trailing P/E —
Price / Book —
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

24-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$150.00K
↓ -32.1% —
Net Income Profit after all expenses
$-28.42M
↓ -71.7% —

Health Breakdown

Returns
58
Financial Health ↓
1
Cash Quality ↑
86

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 7 years · 24 quarters